Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Comparing different treatment approaches to laryngopharyngeal reflux disease
1+ mon, 2+ day ago (413+ words) Canadian Healthcare Network...
The #1 Habit to Start to Poop Better, According to Gastroenterologists
1+ mon, 4+ week ago (12+ words) EatingWell...
Chronic Constipation May Be Linked to Your Gut's 'Second Brain"
1+ mon, 4+ week ago (298+ words) Enjoying consistent, low-effort bowel movements is a massively underappreciated aspect of one's quality of life....
5 Myths About Constipation You Need to Stop Believing, According to Dietitians
2+ mon, 2+ week ago (593+ words) These common constipation myths may be keeping you from finding relief. Deborah Murphy is a food and nutrition blogger, recipe developer, content creator and consulting dietitian. She is an expert in plant-based nutrition and has more than 10 years of experience…...
ABSI: ABS-201 advances in phase II trials, targeting major unmet needs in hair loss and endometriosis
3+ mon, 3+ day ago (84+ words) TradingView ABSI: ABS-201 advances in phase II trials, targeting major unmet needs in hair loss and endometriosis AI-driven drug design has enabled rapid, cost-effective development of ABS-201, now in phase II trials for androgenic alopecia and soon for endometriosis. Preclinical…...
Dayspring Pharma's CG2001 Meets Phase II Endpoint in Male Androgenetic Alopecia Trial
3+ mon, 4+ day ago (180+ words) 09 June 2026 | Tuesday | News CG2001 is a topical fixed-dose combination formulation containing minoxidil and finasteride, being evaluated for the treatment of male androgenetic alopecia. The trial consisted of the following treatment arms: CG2001 (5% Minoxidil and 0.075% Finasteride) once daily (QD); CG2001 (5% Minoxidil and 0.1% Finasteride) once…...
Expert Pearls on the Use of the FoLix Laser for Androgenetic Alopecia
4+ mon, 1+ day ago (113+ words) The Dermatology Digest Expert Pearls on the Use of the FoLix Laser for Androgenetic Alopecia With Dr. Jennifer Krejci Jennifer Krejci, MD, a Dermatologist at the Limmer Hair Transplant Center in San Antonio, TX, recently presented new data on FoLix…...
Is hair loss reversible? New study shifts focus to the scalp ecosystem
4+ mon, 1+ week ago (744+ words) The study highlights how fixing the scalp's structure, not just treating hair, can restart growth by activating key biological pathways Hair loss has long been seen as inevitable, driven by hormones and genetics, but new research is beginning to shift…...
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
4+ mon, 2+ week ago (277+ words) VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 Rapid and robust hair growth was achieved with VDPHL01 treatment…...
Early, rapid growth seen with ’milestone’ hair loss pill: Topline data
4+ mon, 1+ week ago (223+ words) A proprietary extended-release oral minoxidil tablet yielded rapid and robust hair growth in men with pattern hair loss, according to topline results. Data from study 302, a phase 2/3 trial including more than 500 men with androgenic alopecia, suggest VDPHL01 (Veradermics) could potentially become…...